Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.092 | Predictors of Hepatitis B Virus Reactivation after Lamivudine Prophylaxis for Chemotherapy | Prof. Yeo Winnie |
| 2013.417 | GASTRIC CANCER PATIENTS RECEIVING ADJUVANT TS-1- A SURVEY ON PATIENTS’ TOLERABILITY | Prof. YEO Winnie |
| 2012.158 | Design Innovation and Customisation of the Mastectomy Bra and Prosthesis for Hong Kong Mastectomy Patients: A Multidisciplinary Approach | Prof. YEO Winnie |
| 2010.204 | Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B treated with anti-B cell therapy-Effective and Cost-Effectiveness of prevention | Prof. Yeo Winnie |
| 1995.526 | Randomized Trial of High-Dose Epirubicin and Cyclophamide x 3 Supported by Peripheral Blood Projector Cells Versus Anthracycline and Cyclophosphamide x 4 Followed by Cyclophosphamide, Methotrexate & 5- Fluorouracil as Adjuvant Treatment for High Risk Operable Stage II and Stage III Breast Cancer in Premenopausal and Young Postmenopausal (<65 yrs) Patients | Prof. YEO Winnie |
| 2026.230 | A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011) | Prof. YEO Winnie |
| 2020.330 | Scalp Cooling Study for the Prevention of Chemotherapy-induced Alopecia in Chinese Breast Cancer Patients |
Prof. YEO Winnie 楊明明教授 |
| 2020.258 | A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. |
Prof. YEO Winnie 楊明明 |
| 2018.363 | A RETROSPECTIVE STUDY ON EFFICACY AND TOLERABILITY OF COMBINATION FLOT CHEMOTHERAPY AS NEOADJUVANT CHEMOTHERAPY IN GASTRIC CANCER PATIENTS |
Prof. YEO Winnie 楊明明 |
| 2018.435 | A Phase 3, multicenter, randomized, open-label, active-controlled study of Trastuzumab Deruxtecan (DS-8201A), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane (DESTINY-Breast03) |
Prof. YEO Winnie 楊明明 |
| 2019.551 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2019.476 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2018.392 | A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859) |
Prof. YEO Winnie 楊明明 |
| 2018.528 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2016.435 | A prospective study of circulating and urinary isoflavones and lignans concentration at 60-m after diagnosis and the risk of recurrence and mortality in Chinese women with early-stage breast cancer | Prof. YEO Winnie |
| 2015.689 | A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma |
Prof. YEO Winnie 楊明明 |
| 2014.584 | A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer | Prof. YEO Winnie |
| 2015.507 | A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119) |
Prof. YEO Winnie 楊明明 |
| 2017.356 | China local BRCA testing and exploration of ovarian cancer treatment outcomes of different BRCA status in newly diagnosed epithelial ovarian cancer patients |
Prof. YEO Winnie 楊明明 |
| 2014.596 | A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepatocellular Carcinoma (HCC) | Prof. YEO Winnie |
| 2016.010 | Cancer Health Literacy among Chinese cancer patients in Hong Kong | Prof. YEO Winnie |
| 2017.478 | A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer |
Prof. YEO Winnie 楊明明教授 |
| 2016.013 | A Randomized Study to Determine the Efficacy and Tolerability of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese breast cancer patients. |
Prof. YEO Winnie 楊明明 |
| 2017.072 | A Prospective Study on the Role of Pharmacogenomic Study in Association with Chemotherapy-Induced Nausea and Vomiting | Prof. YEO Winnie |
| 2017.320 | A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer |
Prof. YEO Winnie 楊明明 |
| 2015.696 | RETROSPECTIVE REVIEW OF EFFICACY AND TOLERABILITY OF T-DM1 IN ADVANCED HER2+ BREAST CANCER |
Prof. YEO Winnie 楊明明 |
| 2017.169 | Open label single arm study for NEPA [oral fixed-dose combination of 300 mg netupitant and 0.50 mg palonosetron] in Hong Kong oncology patients receiving (neo)-adjuvant chemotherapy treatment consists of adriamycin and cyclophosphamide for breast cancer. | Prof. YEO Winnie |
| 2017.262 | A comparison of 24-h dietary recalls and mobile phone food record among Hong Kong Chinese women with early-stage breast cancer |
Prof. YEO Winnie 楊明明 |
| 2014.460 | A Retrospective Study to Assess the Role of Prophylactic Anti-viral Therapies for Patients with CD20+ Lymphoma Receiving Anti-B cell Therapies | Prof. YEO Winnie |
| 2015.184 | A 60-m prospective study of long-term intake of dietary isoflavones and lignans on the risk of recurrence and mortality in Chinese women with early-stage breast cancer | Prof. YEO Winnie |
| 2016.290 | A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma |
Prof. YEO Winnie 楊明明 |
| 2016.156 | RETROSPECTIVE REVIEW OF TUMOUR CHARACTERISTICS AND OUTCOMES OF BREAST CANCER PATIENTS |
Prof. YEO Winnie 楊明明 |
| 2014.529 | A randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy | Prof. YEO Winnie |
| 2014.078 | The prognostic significance of combination of AFP, DCP and AFP L3 as biomarkers in hepatocellular carcinoma | Prof. YEO Winnie |
| 2023.102 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 | Prof. YEO Winnie Ming Ming |
| 2021.696 | Health Support Pilot Programme for South Asian Ethnic Groups |
Prof. YEOH Eng Kiong 楊永強 |
| 2014.551 | Improving elderly healthcare voucher scheme to incentivise primary care in Hong Kong: How has health service utilization changed | Prof. YEOH Eng Kiong |
| 2017.193 | Modelling the Impact of Control Strategies for Tuberculosis Transmission in Hong Kong | Prof. YEOH Eng Kiong |
| 2015.359 | Quality of healthcare for the Ageing – Health system and service models to better cater for an ageing population | Prof. YEOH Eng Kiong |
| 2020.354 | Tender for the Provision of Services of the Monitoring and Evaluation Study of Kwai Tsing District Health Centre and Sham Shui Po District Health Centre |
Prof. YEOH Eng Kiong 楊永強 |
| 2026.566 | Health Services Utilization and Health Outcomes of HA patients: Population Trend, Individual Trajectories, and Impact of Policy | Prof. Yeoh Eng Kiong |
| 2020.015 | Effects of commercial antimicrobial mouthwash on oral microbial community composition | Dr. YEOH Yun Kit |
| 2018.008 | Genome-based resolution of gut microbiomes and viromes in patients with metabolic syndrome | Dr. YEOH Yun Kit |
| 2017.514 | Gut microbiome of individuals with metabolic syndrome | Dr. YEOH Yun Kit |
| 2005.160 | The Effect of Therapeutics Ultrasound in Healing Reptured Achilles Tendon in Human | YEUNG Chi Keung |
| 2009.279 | How does spinal stenosis affects the health-related quality of life of Chinese older people? | Miss Yeung Chi Yan |
| 2019.438 | Effects of An Advance Care Planning Programme for Persons With Early Dementia or Mild Cognitive Impairment And Their Family Caregivers in the Community: A Randomized Controlled Trial |
Ms. YEUNG Chi Yan 楊智恩 |
| 2017.620 | The effect of posture brace on balance in patients with osteoporotic vertebral fracture |
Miss YEUNG Ching Wing 楊靜穎 |
| 2016.183 | Impact of a Home-based Pharmaceutical Care Service on Medication Adherence and Quality of Life : A prospective observational study |
Ms. YEUNG Ching Ying 楊靜瀅 |
| 2008.147 | Validity and Reliability of Skinfold Thickness Measurement in Assessing Body Density and Body Fatness in Chinese Children in Hong Kong Aged 6-19 Years Using Air Displacement Plethysmography as a Criterion Measure | Mr Yeung Daniel Chi Shing |
Page 274 of 289.